Vivek Subbiah/LinkedIn
Jul 5, 2025, 18:53
Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“July is Sarcoma Awareness Month – it’s a time to shine a light on sarcomas and all rare cancers.
I spoke with TV News Channel 5 about why early detection matters and how clinical trials offer hope for those facing limited options
– Rare doesn’t mean invisible. And awareness is more than a campaign, it’s a call to action
– Every early diagnosis, every trial, every voice, it all matters.”
Watch the video attached to this post.
More posts featuring Vivek Subbiah on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 5, 2025, 20:31
Jul 5, 2025, 20:15
Jul 5, 2025, 20:00
Jul 5, 2025, 19:18
Jul 5, 2025, 18:52
Jul 5, 2025, 18:38